Associations of Sarcopenia and Sarcopenic Obesity With Metabolic Syndrome Considering Both Muscle Mass and Muscle Strength
2
조회
0
다운로드
8
인용
0
참고문헌
키워드
초록
Objectives: We investigated the associations of sarcopenia-defined both in terms of muscle mass and muscle strength-and sarcopenic obesity with metabolic syndrome. Methods: Secondary data pertaining to 309 subjects (85 men and 224 women) were collected from participants in exercise programs at a health center in a suburban area. Muscle mass was measured using bioelectrical impedance analysis, and muscle strength was measured via handgrip strength. Sarcopenia based on muscle mass alone was defined as a weight-adjusted skeletal muscle mass index more than two standard deviations below the mean of a sex-specific young reference group (class II sarcopenia). Two cut-off values for low handgrip strength were used: the first criteria were <26 kg for men and <18 kg for women, and the second criteria were the lowest quintile of handgrip strength among the study subjects. Sarcopenic obesity was defined as the combination of class II sarcopenia and being in the two highest quintiles of total body fat percentage among the subjects. The associations of sarcopenia and sarcopenic obesity with metabolic syndrome were evaluated using logistic regression models. Results: The age-adjusted risk ratios (RRs) of metabolic syndrome being compared in people with or without sarcopenia defined in terms of muscle mass were 1.25 (95% confidence interval [CI], 1.06 to 1.47, p=0.008) in men and 1.12 (95% CI, 1.06 to 1.19, p<0.001) in women, which were found to be statistically significant relationships. The RRs of metabolic syndrome being compared in people with or without sarcopenic obesity were 1.31 in men (95% CI, 1.10 to 1.56, p=0.003) and 1.17 in women (95% CI, 1.10 to 1.25, p<0.001), which were likewise found to be statistically significant relationships. Conclusions: The associations of sarcopenia defined in terms of muscle mass and sarcopenic obesity with metabolic syndrome were statistically significant in both men and women. Therefore, sarcopenia and sarcopenic obesity must be considered as part of the community-based management of non-communicable diseases.
Abstract
Objectives: We investigated the associations of sarcopenia-defined both in terms of muscle mass and muscle strength-and sarcopenic obesity with metabolic syndrome. Methods: Secondary data pertaining to 309 subjects (85 men and 224 women) were collected from participants in exercise programs at a health center in a suburban area. Muscle mass was measured using bioelectrical impedance analysis, and muscle strength was measured via handgrip strength. Sarcopenia based on muscle mass alone was defined as a weight-adjusted skeletal muscle mass index more than two standard deviations below the mean of a sex-specific young reference group (class II sarcopenia). Two cut-off values for low handgrip strength were used: the first criteria were <26 kg for men and <18 kg for women, and the second criteria were the lowest quintile of handgrip strength among the study subjects. Sarcopenic obesity was defined as the combination of class II sarcopenia and being in the two highest quintiles of total body fat percentage among the subjects. The associations of sarcopenia and sarcopenic obesity with metabolic syndrome were evaluated using logistic regression models. Results: The age-adjusted risk ratios (RRs) of metabolic syndrome being compared in people with or without sarcopenia defined in terms of muscle mass were 1.25 (95% confidence interval [CI], 1.06 to 1.47, p=0.008) in men and 1.12 (95% CI, 1.06 to 1.19, p<0.001) in women, which were found to be statistically significant relationships. The RRs of metabolic syndrome being compared in people with or without sarcopenic obesity were 1.31 in men (95% CI, 1.10 to 1.56, p=0.003) and 1.17 in women (95% CI, 1.10 to 1.25, p<0.001), which were likewise found to be statistically significant relationships. Conclusions: The associations of sarcopenia defined in terms of muscle mass and sarcopenic obesity with metabolic syndrome were statistically significant in both men and women. Therefore, sarcopenia and sarcopenic obesity must be considered as part of the community-based management of non-communicable diseases.
참고문헌 (40)
- Shim MS, "A study on duty awareness of public health-center workers", J Korea Conver Soc, 1(1), pp.83~91 (2010)
- 변도화, "민관협력을 통한 고혈압･당뇨병 등록･관리사업의 접근 전략: 홍천군 사례의 정책적 함의", 보건교육건강증진학회지, 30(4), pp.111~123 (2013), 한국보건교육건강증진학회
- Korea health statistics 2013: Korea National Health and Nutrition Examination Survey (KNHANES VI-1), "Ministry of Health and Welfare", Ministry of Health and Welfare, 52~ (2014)
- Ansan community-based cohort study, "Korea University Research and Business Foundation", Korea Centers for Disease Control and Prevention, 84~ (2013)
- Annual report on the causes of death statistics 2013, "Statistics Korea", Statistics Korea, 12~ (2014)
- 홍상모, "Sarcopenia의 최신지견: 근감소증", 대한내과학회지, 83(4), pp.444~454 (2012), 대한내과학회[DOI]
- Rosenberg IH, "Sarcopenia: origins and clinical relevance", J Nutr, 127(5 Suppl), pp.990S~991S (1997)
- Cruz-Jentoft AJ, "Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People", Age Ageing, 39(4), pp.412~423 (2010)
- Balagopal P, "Effects of aging on in vivo synthesis of skeletal muscle myosin heavy-chain and sarcoplasmic protein in humans", Am J Physiol, 273(4 Pt 1), pp.E790~E800 (1997)
- Prado CM, "Sarcopenic obesity: a critical appraisal of the current evidence", Clin Nutr, 31(5), pp.583~601 (2012)
- Hwang J, "Aging and sarcopenia: resistance exercise and protein intake in the elderly", Ewha J Human Move Sci, 12, pp.15~20 (2009)
- Zoico E, "Physical disability and muscular strength in relation to obesity and different body composition indexes in a sample of healthy elderly women", Int J Obes Relat Metab Disord, 28(2), pp.234~241 (2004)
- "Ageing and life-course"[URL]
- Sayer AA, "Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg", Diabetes Care, 28(10), pp.2541~2542 (2005)
- Janssen I, "Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability", J Am Geriatr Soc, 50(5), pp.889~896 (2002)
- Janssen I, "The healthcare costs of sarcopenia in the United States", J Am Geriatr Soc, 52(1), pp.80~85 (2004)
- Gale CR, "Grip strength, body composition, and mortality", Int J Epidemiol, 36(1), pp.228~235 (2007)
- Stenholm S, "Sarcopenic obesity: definition, cause and consequences", Curr Opin Clin Nutr Metab Care, 11(6), pp.693~700 (2008)
- Klip A, "Glucose transport and glucose transporters in muscle and their metabolic regulation", Diabetes Care, 13(3), pp.228~243 (1990)
- Reaven GM, "Banting lecture 1988. Role of insulin resistance in human disease", Diabetes, 37(12), pp.1595~1607 (1988)
- Walsh K, "Adipokines, myokines and cardiovascular disease", Circ J, 73(1), pp.13~18 (2009)
- Solerte SB, "Nutritional supplements with oral amino acid mixtures increases whole-body lean mass and insulin sensitivity in elderly subjects with sarcopenia", Am J Cardiol, 101(11A), pp.69E~77E (2008)
- Sanada K, "A cross-sectional study of sarcopenia in Japanese men and women: reference values and association with cardiovascular risk factors", Eur J Appl Physiol, 110(1), pp.57~65 (2010)
- Chien MY, "Prevalence of sarcopenia estimated using a bioelectrical impedance analysis prediction equation in community-dwelling elderly people in Taiwan", J Am Geriatr Soc, 56(9), pp.1710~1715 (2008)
- Chen LK, "Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia", J Am Med Dir Assoc, 15(2), pp.95~101 (2014)
- Srikanthan P, "Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III", PLoS One, 5(5), pp.e10805~ (2010)
- Moon SS, "Low skeletal muscle mass is associated with insulin resistance, diabetes, and metabolic syndrome in the Korean population: the Korea National Health and Nutrition Examination Survey (KNHANES) 2009-2010", Endocr J, 61(1), pp.61~70 (2014)
- Kim TN, "Prevalence of sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study", Int J Obes (Lond), 33(8), pp.885~892 (2009)
- Lauretani F, "Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia", J Appl Physiol (1985), 95(5), pp.1851~1860 (2003)
- Janssen I, "Estimation of skeletal muscle mass by bioelectrical impedance analysis", J Appl Physiol (1985), 89(2), pp.465~471 (2000)
- Janssen I, "Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women", Am J Epidemiol, 159(4), pp.413~421 (2004)
- Kim YS, "Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the Fourth Korean National Health and Nutritional Examination Surveys", J Gerontol A Biol Sci Med Sci, 67(10), pp.1107~1113 (2012)
- Grundy SM, "Diagnosis and management of the metabolic syndrome: an American Heart Association", National Heart, Lung, and Blood Institute Scientific Statement, 2005, pp.112(17), 2735~2752
- 박은옥, "제 5기 국민건강영양조사로 추정한 한국 성인의 대사증후군 유병률과 관련 요인", 농촌의학.지역보건, 38(1), pp.1~13 (2013), 한국농촌의학.지역보건학회
- Sayer AA, "Grip strength and the metabolic syndrome: findings from the Hertfordshire Cohort Study", QJM, 100(11), pp.707~713 (2007)
- Gaster M, "GLUT4 expression at the plasma membrane is related to fibre volume in human skeletal muscle fibres", APMIS, 110(9), pp.611~619 (2002)
- Roubenoff R, "Sarcopenic obesity: the confluence of two epidemics", Obes Res, 12(6), pp.887~888 (2004)
- Roubenoff R, "Catabolism of aging: is it an inflammatory process", Curr Opin Clin Nutr Metab Care, 6(3), pp.295~299 (2003)
- Tanimoto Y, "Association between sarcopenia and higher-level functional capacity in daily living in community-dwelling elderly subjects in Japan", Arch Gerontol Geriatr, 55(2), pp.e9~e13 (2012)
- Tieland M, "Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: a randomized, double-blind, placebo-controlled trial", J Am Med Dir Assoc, 13(8), pp.713~719 (2012)